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Abstract 
Background: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome that 
has been associated with changes in the extracellular matrix. The purpose of this study was to 
determine whether profibrotic biomarkers accurately reflect the presence and severity of disease, 
underlying pathophysiology and modify response to therapy in patients with HFpEF. 
 
Methods and Results: Four biomarkers, soluble form of ST2(sST-2, an Interleukin-1 receptor 
family member), galectin-3(gal-3), matrix metalloproteinase-2(MMP-2) and collagen III n-
terminal propeptide(PIIINP) were measured in the Prospective comparison of ARNI with ARB 
on management of heart failure with preserved ejection fraction (PARAMOUNT) trial at 
baseline, 12 and 36 weeks after randomization to valsartan or LCZ696. We examined the 
relationship between baseline biomarkers, demographic and echocardiographic characteristics, 
change in primary (change in n-terminal pro B-type natriuretic peptide[NT-proBNP]) and 
secondary (change in left atrial volume[LAV]) endpoints. The median (interquartile range) value 
for sST-2(33 [24.6, 48.1] ng/mL) and gal-3(17.8[14.1, 22.8] ng/mL) were higher, and MMP-
2(188 [155.5, 230.6] ng/mL) lower, than in previously published referent controls; PIIINP(5.6 
[4.3, 6.9] ng/mL) was similar to referent control values. All 4 biomarkers correlated with severity 
of disease as indicated by NT-proBNP, E/E’ and LAV. Baseline biomarkers did not modify the 
response to LCZ696 for lowering NT-proBNP; however, LAV reduction varied by baseline level 
of sST2 and gal-3; patients with values < the observed median (<33 ng/mL sST-2, <17.8 ng/mL 
gal-3) had reduction in LAV, those above median did not. While LCZ696 reduced NT-proBNP 
levels of the other four biomarkers were not affected over time. 
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Conclusions: In HFpEF patients, biomarkers that reflect collagen homeostasis correlated with 
the presence and severity of disease, underlying pathophysiology, and may modify the structural 
response to treatment. 
Word count: 250 
 
Clinical Trial Registration: This trial is registered at ClinicalTrials.gov, NCT00887588, 
https://clinicaltrials.gov/ct2/show/NCT00887588 
 
Key Words: Biomarker; Chronic Heart Failure, Preserved Ejection Fraction. 
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Short Commentary 
 
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome that has been 
associated with changes in the extracellular matrix. The purpose of this analysis was to examine 
a selected portfolio of postulated profibrotic biomarkers in a defined population of HFpEF, relate 
these biomarkers to demographic characteristics, changes in LV structure and function, severity 
of disease and response to treatment. Data from this analysis support several novel and 
hypothesis generating findings. First, HFpEF patients have circulating biomarkers that reflect a 
profibrotic state. Gal-3 and sST-2 were increased and MMP-2 was decreased. In aggregate, these 
directional changes in these biomarkers might be expected to be associated with an increase in 
myocardial collagen content. Second, biomarker levels correlate with indices of disease severity. 
While each of the patients enrolled in PARAMOUNT had the clinical syndrome of HFpEF, 
those with the more severe disease had a biomarker pattern associated with a more profibrotic 
milieu. Third, the baseline pretreatment values of sST-2 and gal-3 may have modified the 
response to LCZ696, specifically reduction in Left Atrial (LA) volume. Patients who had levels 
of sST-2 and Gal-3 below the observed median value showed a greater LA volume response to 
LCZ696 than those with sST-2 and Gal-3 above the median. In HFpEF patients, biomarkers that 
reflect collagen homeostasis correlated with the presence and severity of disease, underlying 
pathophysiology, and may modify the structural response to treatment. 
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Introduction 
 
 A number of novel circulating biomarkers have been used to characterize the molecular and 
cellular changes that occur during the development of myocardial disease (1-4). In heart failure 
(HF) these include biomarkers that reflect hemodynamic status (such as natriuretic peptides), 
inflammation (such as interleukins), and collagen homeostasis (such as collagen peptides, 
interstitial proteases) (2). The profiles of these biomarkers appear to differ significantly in 
patients with HF with a reduced ejection fraction (EF) versus HF with a preserved EF (HFpEF) 
(5-7). The nature and extent to which biomarkers change in HFpEF as a function of disease 
severity, degree of left ventricular (LV) structural and functional abnormalities and 
demographics and co-morbid conditions have not been fully defined. In addition, whether 
baseline biomarkers can modify the response to treatment in HFpEF has not been examined. One 
potential mechanism hypothesized to play a pivotal role in the development HFpEF is a change 
in collagen homeostasis that results in extracellular matrix (ECM) fibrosis and the development 
of abnormal diastolic function (8-12). Several molecular and cellular signaling pathways that 
result in a profibrotic milieu have been identified in previous studies but have not been 
specifically examined in randomized clinical trials in HFpEF (2, 6, 7). 
 Patients enrolled in the Prospective comparison of ARNI with ARB on management of heart 
failure with preserved ejection fraction trial (PARAMOUNT) had the clinical syndrome of heart 
failure and evidence of increased LV filling pressures (symptoms and signs of volume overload 
and increased n-terminal pro B-type natriuretic peptide [NT-proBNP]) (13). We hypothesized 
that if changes in ECM fibrillar collagen content lead to abnormal diastolic function, these 
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patients should have changes in biomarkers reflecting this. The purpose of this study was to 
examine a selected portfolio of postulated profibrotic biomarkers in a defined population of 
HFpEF, relate these biomarkers to demographic characteristics, changes in LV structure and 
function, severity of disease and response to treatment. Given the post-hoc nature of this analysis 
and its modest sample size, this study was envisioned as hypothesis generating providing 
provocative evidence that would lead to additional, larger, more definitive studies. 
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Methods 
Study Design 
 PARAMOUNT was a randomized, double-blind, parallel group, active control trial described 
in detail in previous publications (13). Briefly, men and women ≥ 40 years old with an LVEF ≥ 
45% and a documented history of heart failure with associated signs or symptoms (dyspnea on 
exertion, orthopnea, paroxysmal dyspnea, and peripheral edema) were eligible. Patients were 
required to have NT-proBNP greater than 400 pg/mL at screening, be on diuretic therapy, and 
have a systolic blood pressure < 140 mm Hg, or 160 mm Hg or less if on three or more blood 
pressure drugs at randomization, have an estimated glomerular filtration rate (eGFR) of at least 
30 mL/min per 1·73 m² at screening, and a potassium concentration of no more than 5·2 
mmol/L. Patients were excluded if they had previous LVEF < 45% at any time, isolated right 
heart failure due to pulmonary disease, dyspnea due to non-cardiac causes such as pulmonary 
disease, anemia, or severe obesity, primary valvular or myocardial diseases, or coronary artery or 
cerebrovascular disease needing revascularization within 3 months of screening or likely to need 
revascularization during the trial. The number of patients enrolled with atrial fibrillation on ECG 
at screening was limited to roughly 25% of the total. The study protocol was submitted to 
individual sites’ institutional review boards or ethics committees and all enrolled patients 
provided written informed consent. A data safety monitoring committee oversaw the program 
and reviewed trial data for patient safety at regular intervals. 
 
Biomarkers 
 Plasma and serum were obtained for biomarker determination at baseline, 12, and 36 weeks 
after randomization. The baseline measurements were made at randomization following a 
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placebo run-in phase. Measurements after randomization to Valsartan or LCZ696 were made 12 
and 36 weeks. NT-proBNP and matrix metalloproteinase-2 (MMP-2) were measured in plasma 
and collagen III n-terminal propeptide (PIIINP) was measured in serum at Quest Diagnostics 
(Valencia, CA, USA) using the Elecsys proBNP immunoassay (Roche Diagnostics, Indianapolis, 
IN, USA), the Quantikine MMP-2 immunoassay (R and D Systems, Minneapolis, MN, USA) 
and the UniQ PIIINP radioimmunoassay (Orion Diagnostics, Espoo, FIN). The soluble form of 
ST-2 (sST-2, an Interleukin-1 receptor family member) was measured in serum at Critical 
Diagnostics (San Diego, CA, USA) using their Presage® immunoassay and Galectin 3 (Gal-3) 
was measured in serum at Clinical Reference Laboratories (Lenexa, KS, USA) using an enzyme-
linked immunosorbent assay (BG Medicine, Waltham, MA. USA). 
 
Echocardiographic study 
 Baseline echocardiograms were analyzed in the cardiovascular imaging core laboratory at 
Brigham and Women’s Hospital, Boston MA, USA. All measurements were made in triplicate in 
accordance with the recommendations of the American Society of Echocardiography (ASE) (14). 
Left ventricular (LV) volumes, mass (LVM), relative wall thickness (RWT), mitral flow 
velocities, tissue Doppler velocities, left atrial volume, LVEF were calculated according to the 
recommendations of the American Society of Echocardiography (14). Left atrial strain and LV 
global longitudinal strain were measured using vendor-independent 2D speckle tracking software 
(15). 
 
Statistical Analysis 
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 Baseline characteristics were summarized by quartiles of each biomarker using counts and 
percentages for binary variables and means and standard deviations for continuous variables, 
with the exception of NT-proBNP, which is summarized via median [IQR] due to skewness. Tests for 
trend across quartiles were conducted via chi-square trend tests, linear regression, and Cuzick’s 
non-parametric trend test, as appropriate. Biomarker data were presented as mean ± SEM, 
geometric mean, and median [IQR] at baseline. Baseline biomarker data were compared to data 
measured at 12 and 36 weeks after randomization presented as median [IQR] for the entire study 
group and then divided according to treatment group (Valsartan vs. LCZ696). 
 Baseline biomarker data were compared qualitatively with referent control values. Referent 
control values were presented for comparison as median [IQR]. Median [IQR] referent control 
data for PIIINP and MMP-2 were taken from a previously published study in which 241 subjects 
of age, sex, race distribution similar to the current study population were examined (5). 
However, these well characterized subjects had no clinical, serologic, or cardiac 
structural/functional abnormalities as evidenced by a normal echocardiography and 6 minute hall 
walk distance. Median [IQR] referent control data for Gal-3 were taken from a previously 
published study in which 1092 subjects of age, sex, race distribution similar to the current study 
population were examined (33). Median [IQR] referent control data for sST-2 were aggregated 
from 3 previously published study (including the Framingham study) in which subjects of age, 
sex, race distribution similar to the current study population were examined (34-37). While small 
differences between men and women have been seen in the biomarkers described above, since 
the populations of both the current study and the referent control populations are roughly 50% 
female, the referent control values listed in Table 1 represent the total population examined. In 
addition, biomarker data from the current study of HFpEF patients were compared to previously 
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published groups of HFpEF patients (5, 38-41). Finally, Gal-3 and sST-2 data in the current 
study were compared to FDA approved partition values for risk stratification; these partition 
values were not specifically designed for risk stratification in HFpEF but were targeted to overall 
risk in generalized populations. 
 Correlations between biomarkers and demographic and echocardiographic data were 
performed using Spearman’s correlation. Values for sST-2, gal-3 and NT-proBNP were log-
transformed because they were noticeably right-skewed. In a multivariable regression model that 
included age, sex, NYHA class, history of AF, diastolic blood pressure, eGFR, log NT-pro BNP, 
LV transmitral early diastolic filling velocity / LV early diastolic myocardial velocity (E/E’), and 
LA volume we examined which factors were independently associated with baseline levels of 
biomarkers. Variables included were on the basis of low numbers of missing values and clinical 
knowledge. To examine the interaction between treatment with LCZ696 and baseline biomarker 
levels on levels of NT-proBNP at 12 weeks and LA volume at 36 weeks we used a regression 
model which included the effect of LCZ696, an interaction term between treatment and baseline 
biomarker values and stratification variables of region and prior ACE-I or ARB use as well as 
baseline NT-proBNP and LA volume respectively. Where an interaction was found this was 
explored further by dividing the cohort into values above and below the observed median value 
of the biomarker and stratified models of the effect of treatment on NT-proBNP and LA volume 
examined. All statistical analyses were performed using STATA version 12 (Stata Corp, College 
Station, TX, USA). For interaction tests a P value <0.1 was considered suggestive of an 
interaction and for all other test a P value<0.05 was considered statistically significant. 
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Results 
 
Demographic and Echocardiographic Data 
 Data from the 301 randomized patients were included in this study, 149 randomized to 
LCZ696, 152 to valsartan. The demographic and echocardiographic data were typical of a stable 
outpatient HFpEF population (31,32); elderly, female and NYHA Class II dominant, receiving 
multi-drug treatment, expected co-morbidities, and evidence of abnormal diastolic function with 
increased NT-proBNP, E/E’, and LA volume. Baseline data are presented for each individual 
biomarker examined by quartiles (Supplemental Tables 1-4). 
 
Baseline Biomarker Data 
 In these HFpEF patients, the baseline median values for gal-3 and sST-2, summarized in 
Table 1, were ~50% higher than the median values from previously published referent control 
subjects (33-41). In these HFpEF patients, the median values for MMP-2 were ~50% lower and 
PIIINP were similar to previously published referent control subjects (5, 42). 
 There were significant correlations between baseline biomarkers and demographic and 
echocardiographic variables (Table 2). Gal-3, sST-2 and PIIINP increased and MMP-2 decreased 
in association with an increase in NT-proBNP, and decreased eGFR (Figure 1A). sST-2 
increased and MMP-2 decreased in association with an increase in E/E’ and LA volume (Figure 
1B). There was also a direct relationship between sST-2 and gal-3 (r=0.24, p<0.001, Figure 1C).  
 In a multivariable model after adjusting for age, sex, NYHA class, history of atrial 
fibrillation, diastolic blood pressure, eGFR, log NT-proBNP, E/E’, and LA volume, only female 
sex (coef -0.27(95%CI -0.40 – -0.14), p<0.001), NYHA class (coef 0.24 (0.09 -0.39), p=0.002) 
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and LA volume (coef 0.003(0.0004 – 0.005),p=0.02) were statistically significantly associated 
with higher sST2. Only female sex (coef 0.168(0.004-0.332), p=0.04) and log NT-proBNP (coef 
0.10 (0.01 - 0.19), p=0.03) were associated with baseline PIIINP. Lower diastolic blood pressure 
was associated with higher MMP2 levels at baseline (coef -0.014(-0.023 - -0.006), p=0.001) 
whereas lower eGFR was associated with higher Gal-3 (coef -0.008 (-0.011 - -0.006), p<0.001). 
 
Relationship between Biomarkers and LCZ696 Treatment 
 The relationship between biomarkers and the effects of LCZ696 on the primary study 
endpoint (change in NT-proBNP after 12 weeks of treatment) and the secondary study endpoint 
(change LA volume from baseline after 36 weeks of treatment) were examined. There were no 
treatment interactions between LCZ696 and changes in NT-proBNP at 12 weeks (primary 
endpoint) for any of the four biomarkers; MMP-2 (interaction p=0.40), PIIINP (interaction 
p=0.14), Gal-3 (interaction p=0.32) or sST2 (interaction p=0.63). In addition, there were no 
treatment interactions between LCZ696 and changes in NT-proBNP at 36 weeks for any of the 
four biomarkers; MMP-2 (interaction p=0.09), PIIINP (interaction p=0.5), Gal-3 (interaction 
p=0.2) or sST2 (interaction p=0.99). However, there was an interaction between the response to 
treatment with LCZ696 compared to valsartan on change in LA volume at 36 weeks and baseline 
values of sST-2 (interaction p=0.07) and gal-3 (interaction p= 0.04). There was no interaction 
with PIIINP levels (interaction p=0.79) or MMP2 (interaction p= 0.61).  
 We further explored the interaction with sST-2 and gal-3 by dividing patients into 2 groups, 
for those above and below the observed baseline median value of sST-2 (≥ vs. < 33.0 ng/mL) or 
gal-3 (≥ vs. < 17.8 ng/mL). The effect on change in LA volume from baseline differed between 
LCZ696 and valsartan (Figure 2). In patients with a baseline value of sST-2 above the median, 
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36 weeks of treatment with LCZ696 did not result in a significant change in LA volume from 
baseline compared to valsartan (difference -1.5, 95%CI -7.8 to 4.8, p=0.6 ). Similarly in patients 
with a baseline value of gal-3 above the median, treatment with LCZ696 did not result in a 
significant change in LA volume from baseline compared to valsartan (difference -1.8, 95%CI -
7.6 to 4.0, p=0.5). In patients with a baseline value of sST-2 or gal-3 below the median, 36 weeks 
of treatment with LCZ696 resulted in a statistically significantly larger change from baseline in 
LA volume compared to valsartan (in those with sST-2 values below median, the difference in 
treatment effect between LCZ696 vs. valsartan was -9.9, 95%CI -15.1 to -4.8, p < 0.0001, in 
those with gal-3 values below the median treatment effect between LCZ696 vs. valsartan was 
median difference -10.3, 95%CI -15.6 to -5.0, p < 0.0001). 
 For both patients with an NT-proBNP < median (difference -4.1, 95%CI -9.0, 0.7; p=0.09) 
and patients with an NT-proBNP > median (difference -6.0, 95%CI -12.0, 0.1; p=0.053), 
treatment with LCZ696 resulted in a numerically greater reduction in LA volume from baseline 
compared to valsartan. A formal test of the interaction between randomized treatment and 
baseline NT-proBNP was not statistically significant (p for interaction = 0.12). For patients with 
an eGFR < median (difference -2.8, 95%CI -7.7, 2.1; p=0.26) and patients with an eGFR > 
median (difference -8.8, 95%CI -15.0, -2.6; p=0.006), treatment with LCZ696 resulted in a 
numerically greater reduction in LA volume from baseline compared to valsartan. This change 
was statistically significant for the group with an eGFR > median. However a formal test of 
interaction between randomized treatment and baseline eGFR was not statistically significant (p 
for interaction = 0.58). 
 Interactions between LCZ696 and all other echocardiographic measurements of cardiac 
structure and function for the four biomarkers examined in this study were not performed 
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because they were not listed as a priori endpoints and because our previous published studies 
showed that LCZ696 did not result in a change in any of these other echocardiographic 
parameters (13). 
 There were no significant differences in any of the four biomarker values (sST-2, gal-3, 
MMP-2, or PIIINP) between patients treated with Valsartan versus LCZ696 at baseline or after 
12 or 36 weeks of treatment (Table 3). This was true for the patient group as a whole and for 
subgroups with baseline sST-2 and gal-3 above and below the observed median values. 
Comparing baseline biomarker values to after treatment values, MMP-2 increased significantly 
in both valsartan and LCZ696 treated patients at week 36 versus baseline (p<0.001);there were 
no significant changes in the other three biomarkers comparing baseline to after treatment values. 
 History of atrial fibrillation was not associated with change in LA volume at 36 weeks 
p=0.12 and there was no interaction between randomized treatment and history of atrial 
fibrillation on change in LA volume p=0.44. In addition, for subjects with AF on ECG at 
baseline, the respective p values were also non-significant at 0.39 and 0.52. 
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Discussion 
 
 Data from the current study support several novel and hypothesis generating findings. First, 
we found that HFpEF patients had values of circulating biomarkers that may reflect a profibrotic 
state. Gal-3 and sST-2 were increased and MMP-2 was decreased. Gal-3 and sST-2 have been 
shown to increase collagen synthesis in cardiac fibroblasts and MMP-2 has been shown to cause 
collagen degradation (2) (Figure 3). In aggregate, the directional changes in these biomarkers 
might be expected to be associated with an increase in myocardial collagen content. The current 
study adds important, novel, clinically relevant data in a group of patients in which there is a 
large gap in knowledge. In particular, the panel of specific biomarkers used in this study has not 
been examined together in previous clinical studies or randomized clinic trials (RCTs) of HFpEF 
patients. In addition, PARAMOUNT represents the only Phase II RCT of HFpEF patients in 
which the pre-specified primary endpoints have been positively improved by the therapy being 
tested. This provided a unique opportunity to examine the purposes proposed and test the 
hypotheses stated in this study. 
 The differences between biomarkers in the current HFpEF patients and referent controls are 
concordant with trends found in the very limited number of other studies that included HFpEF 
patients. For example, in studies including HFpEF patients sST-2 median values ranged from 
~25-30 ng/ml (2, 40-42); Gal-3 median values ranged from ~12-14 ng/ml (2,38,39,42). 
Variations in inclusion/exclusion criteria creating differences in population characteristics, co-
morbidity distribution, and severity of HF are likely responsible for small differences between 
studies. 
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 For both sST-2 and Gal-3 there are FDA approved partition values that can be used in risk 
assessment analyses to predict morbid and mortal outcomes. When sST-2 is > 35 ng/ml or Gal-3 
is > 17.8 ng/ml, there is an increase in risk. It should be noted; however, that both of these 
partition values were established from studies like HF-ACTION and others in which HFrEF 
patients were exclusively or dominantly the focus of study. It is fortuitous that the median values 
for these two biomarkers in the current study are identical to or very close to the FDA approved 
partition values. Therefore, these data lend credence to the important biomarker observations 
made in this study of HFpEF patients in PARAMOUNT. 
 Second, we found that biomarker levels correlated with indices of disease severity. The 
presence of more severe HFpEF is generally indicated by higher levels of NT-proBNP, diastolic 
function (such as E/E’ and LAV) and decreased renal function (2, 5, 16-19). In the current study, 
there was a direct relationship between sST-2 and each of these indices of disease severity; there 
was an inverse relationship with MMP-2. Thus, while each of the patients enrolled in 
PARAMOUNT had the clinical syndrome of HFpEF, those with the more severe disease had a 
biomarker pattern associated with a more profibrotic milieu. While these interactions described 
in the current study may have been expected, they have never been previously examined in a 
substantially sized study of HFpEF patients. The interactions defined help to clarify signaling 
pathways that contribute to fibrosis-induced (and probably inflammation-induced) abnormalities 
in structure and function in HFpEF patients. 
 Third, the baseline pretreatment values of sST-2 and gal-3 may have modified the response 
to LCZ696, specifically reduction in LA volume but not NT-proBNP. Patients who had levels of 
sST-2 and Gal-3 below the observed median value showed a greater LA volume response to 
LCZ696 than those with sST-2 and Gal-3 above the median. These data are clearly not 
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conclusive; however, they do allow the generation of important new hypotheses, particularly 
concerning the mechanisms underlying HFpEF and the effects of LCZ696 on these mechanisms. 
It is possible that patients with less severe myocardial fibrosis may be more responsive to 
treatment, particularly over a short period of treatment. Changes in LV structural remodeling 
may not be detectable until treatment has been continued for at least 12 months. Confirmation of 
these findings in a larger patient cohort and extension of treatment duration will clearly be 
needed in future studies to make more definitive conclusions. These kind of analyses are planned 
for PARAGON-HF. 
 There are several possible factors that contribute to the fact that baseline biomarkers 
modified the response to LCZ696 on LAV but not NT-proBNP. For example, changes in 
natriuretic peptides and changes in left atrial structure / function may reflect different but 
interdependent aspects of the pathophysiologic mechanisms that underlie HFpEF. As presented 
in a previously published schematic, LV diastolic filling pressures can be changed rapidly as a 
result of intravascular volume shifts and a change in operative compliance (2). This 
“hemodynamic” change may be best reflected by changes in natriuretic peptides. LV diastolic 
filling pressures can also be changed more slowly by progressive fibrosis and a change in overall 
chamber compliance (2). This “structural” change may be best reflected by changes in left atrial 
volume. LCZ696 is likely to act on both of these mechanisms. Its direct diuretic, unloading, 
hemodynamic effect would be expected to rapidly reduce filling volume, operative compliance 
and NT-proBNP and to do so without needed to also affect structural changes in myocardial 
ECM collagen or LAV. Therefore, the extent of fibrosis (as reflected by sST-2 or Gal-3) should 
not modify the effects of LCZ696 on changes in NT-proBNP. By contrast, the effects of LCZ696 
on the regression of fibrosis would be expected to occur over longer time periods. Therefore, 
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patients with less fibrosis (as reflected by lower values of sST-2 or Gal-3) may respond more 
quickly with a decrease in overall chamber compliance and a resultant decrease in LAV because 
there was simply less fibrosis to regress. Patients with more fibrosis may take longer than 6-9 
months to respond to LCZ696; however, this finding does not necessarily signal the absence of a 
response. There are few studies that document the time course of regression of fibrosis in 
pathophysiologic processes that undergo treatments that effectively correct the pathophysiologic 
abnormalities. However, perhaps the best example is the effects of aortic valve replacement 
(AVR) in patients with aortic valve stenosis. In these studies, the complete reversal of left 
ventricular fibrosis was time dependent and progressive over a 2-4 year period after AVR (43). 
Thus, the interplay between changes in hemodynamic and structural factors (and other factors) 
may contribute to the findings presented in the current study. 
 Fourth, over the 36 week course of this study, sST-2, gal-3, MMP-2, or PIIINP did not 
change in either the valsartan or LCZ696 treated groups. The significance of this finding is not 
entirely clear. The same possible factors listed above may be applicable such as the length of the 
treatment period may be too short to see significant changes in these biomarkers. Conversely, it 
is possible that this particular set of biomarkers may have greater utility as diagnostic, prognostic 
and severity of illness indices rather than indices reflecting response to therapy. 
 
Biomarkers Reflecting a Profibrotic State 
 Fibrillar collagen content can be altered by changes in the balance in the following processes: 
collagen synthesis, post-synthetic processing and degradation. Biomarkers reflecting changes in 
these processes or their determinants were examined in PARAMOUNT (2, 5-7). For example, 
Gal-3, a beta-galactoside-binding lectin, secreted by macrophages, may act to increase fibroblast 
20  
 
 
proliferation, activity, transformation into myofibroblast and increase collagen synthesis (20-30). 
Likewise, soluble ST2, by acting as a decoy, prevents binding of IL-33 to membrane-bound ST2 
and results in increased collagen synthesis (Figure 3). Therefore, both gal-3 and sST2 induced 
increase in collagen synthesis would be expected to be reflected in an increase in levels of 
collagen propeptides such as PIIINP (procollagen III N-terminal propeptide). However, in the 
presence of what appear to be profibrotic stimuli, we did not see changes in PIIINP. It is likely 
that the most important changes in myocardial collagen homeostasis involve a change in 
collagen I rather than collagen III, thus limiting the sensitivity of PIIINP vs measurements of 
collagen I propeptides. In addition to changes in synthesis, changes in degradation may affect 
collagen content. Insoluble collagen fibril degradation is caused by proteases such as matrix 
metalloproteinases (MMP), of which there are > 29 known members (5-11). Only MMP-2 was 
measured in PARAMOUNT; lower values seen in HFpEF patients suggests decreased 
degradation rates; however, measurement of this single MMP particularly without measurement 
of tissue inhibitors of MMPs (TIMPs) does not fully characterize the stoichiometric balance of 
this enzyme system. 
 
Study Limitations 
 We readily acknowledge that comparing biomarker data from the current study with non-
simultaneous, historic, previously published referent controls imposes clear limitations. While a 
referent control group was not included in the design of the PARAMOUNT study, the previously 
published referent control subjects used for comparison were taken from subjects with an age, 
sex, and race distribution similar to the current study population but with no evidence of active 
cardiovascular disease. In addition, the methodologies used in the current study to measure 
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biomarkers were either identical to or equivalent to the methods used in previously published 
studies. The small differences in methodologies are not likely to impose significant differences 
between study analyses. 
 Measurements of circulating biomarkers are not direct measurements of myocardial collagen 
homeostasis. Our analysis assumes that biomarkers are representatively excreted in a manner 
measureable in the circulation and that their predominant source is the myocardium. 
PARAMOUNT was designed with exclusion criteria that limited co-morbid conditions that 
would produce non-myocardial sources of circulating biomarkers that reflect changes in collagen 
homeostasis such a severe renal, pulmonary or hepatic fibrosis.  
 
Conclusion 
 In HFpEF patients, biomarkers that reflect collagen homeostasis correlated with the presence 
and severity of disease, underlying pathophysiology, and may modify the structural response to 
treatment. 
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Table 1: Biomarker Data 
  PARAMOUNT-HF HFpEF Patients  Referent Controls  
 Mean (SD) Geo Mean Median (IQR) Median*   
sST2 (ng/mL) 39.6 (24.7) 34.7 33.0 (24.6, 48.1)  20 (17, 26)  
Galectin-3 (ng/mL) 19.0 (6.9) 17.9 17.8 (14.1, 22.8)  12 (9, 15)  
MMP-2 (ng/mL) 198 (73) 184 188 (156, 231)  335 (323, 443)  
PIIINP (ng/mL) 6.1 (3.5) 5.5 5.6 (4.3, 6.9)  6.5 (6.1, 8.2)  
 
Abbreviation: 
PIIINP = collagen III n-terminal propeptide, MMPs = matrix metaloproteinases, sST-2 = soluble 
form of ST2 (an Interleukin-1 receptor family member), SD = standard deviation, 
IQR=interquartile range. *=Referent control median [IQR] values taken from references 5, 34-
37. 
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Table 2: Correlations Between Biomarker and Demographic/Echocardiographic Data 
 
       
  ST2  Galectin  MMP2  PIIINP 
 R  P R  P R  P R  P  
NT-proBNP 0.19 0.002  0.17 0.004  0.31 <0.001  0.25 <0.001 
eGFR -0.16 0.005  -0.50 <0.001  -0.19 0.002  -0.14 0.07 
SBP -0.03 0.64  0.01 0.94  0.01 0.92  -0.04 0.60 
E' 0.07 0.31  -0.04 0.51  0.07 0.31  0.07 0.38 
E/A 0.12 0.11  -0.04 0.57  0.24 0.003  -0.02 0.84 
E/E' 0.11 0.09  0.09 0.18  0.17 0.01  -0.03 0.70 
LA volume 0.25 <0.001  -0.01  0.87  0.14 0.03  -0.04 0.65  
 
Abbreviation: 
PIIINP = collagen III n-terminal propeptide, MMPs = matrix metaloproteinases, sST-2 = soluble 
form of ST2(an Interleukin-1 receptor family member). E = early diastolic filling velocity, E’ = 
early diastolic myocardial velocity, A = atrial contraction induced diastolic filling velocity wave, 
LA = left atrium, eGFR = estimated glomerular filtration rate, NT-proBNP = N-terminal pro-B-
type natriuretic peptide, SBP = systolic blood pressure. 
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Table 3: Serial Measurements of Plasma Biomarkers 
       
 sST2 Galectin-3 MMP-2 PIIINP  
 
Baseline 
Sample Size: 296 294 247 178 
All 33.0 [24.6,48.1] 17.8 [14.1, 22.8] 188 [156, 231] 5.6 [4.3, 6.9]  
Valsartan 33.8 [25.2, 48.1] 16.9 [14.0, 22.4] 188 [156, 244] 5.6 [4.3, 6.8]  
LCZ696 32.2 [24.3, 47.8] 18.9 [14.4, 23.3] 187 [150, 225] 5.5 [4.4, 7.2]  
 
12 Weeks  
Sample Size: 262 250 244 
All 30.7 [23.4, 44.7] 17.0 [13.9, 22.1] 191 [155, 234]    
Valsartan 31.0 [23.9, 44.4] 17.1 [13.9, 21.2] 194 [150, 243]    
LCZ696 29.8 [23.3, 45.8] 16.9 [14.2, 22.2] 189 [158, 222]    
 
36 Weeks  
Sample Size: 211 214 241 182 
All 33.4 [23.5, 48.4] 16.8 [13.8, 21.9] 253 [208, 318] 5.3 [4.2, 7.1]  
Valsartan 35.2 [23.6, 45.1] 16.8 [13.8, 21.2] 261 [212, 334] 5.4 [4.1, 7.0]  
LCZ696 31.4 [23.5, 50.4] 17.0 [13.8, 22.2] 248 [206, 303] 5.3 [4.2, 7.2]  
       
 
Abbreviation: 
All data are Median (interquartile range) and in units of ng/ml. PIIINP = collagen III n-terminal 
propeptide, MMPs = matrix metaloproteinases, sST-2 = soluble form of ST2 (an Interleukin-1 
receptor family member). 
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Figure Legends 
 
Figure 1: Panel A: Relationship between ln(sST-2) and ln(NT-proBNP) in patients with heart 
failure with a preserved ejection fraction; Spearman correlation r=0.19, p=0.002. Panel B: 
Relationship between ln(sST2) and left atrial volume in patients with heart failure with a 
preserved ejection fraction; correlation r=0.25, p=0.002. Panel C: Relationship between 
ln(sST2) and ln(Gal-3) in patients with heart failure with a preserved ejection fraction; 
correlation r=0.23, p<0.0001. sST-2 = soluble suppressor of tumorigenicity-2; NT-proBNP = n-
terminal pro b-type natriuretic peptide; Gal-3 = Galectin 3. 
 
 
Figure 2: Change from baseline in left atrial volume (LAV) produced by treatment with LCZ696 
versus valsartan in those with a baseline value of sST-2 and gal-3 above and below the median. 
When patients were divided into 2 groups, above and below the baseline median value of sST-2 
or gal-3, the effect on change in LA volume produced LCZ696 vs. valsartan differed; in patients 
with a baseline value of sST-2 or gal-3 above the median, treatment with LCZ696 did not result 
in a significant change in LA volume; in patients with a baseline value of sST-2 or gal-3 below 
the median, treatment with LCZ696 resulted in a decrease in LA volume after 36 weeks of 
treatment compared to baseline. 
 
Figure 3: Schematic representation of mechanisms suggested by changes in circulating 
biomarkers. Increased gal-3 secreted by mast cells may contribute to transdifferentiation of 
fibroblasts to myofibroblasts. Increased sST-2 may contribute to ST-2 profibrotic signaling. 
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Decreased MMP-2 may contribute to less collagen degradation. In aggregate, these changes may 
contribute to increased myocardial ECM collagen and fibrosis and may be reflected by the 
changes measured in circulating biomarkers. 
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Figure 1A
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Figure 1B 
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Figure 1C 
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Figure 3 
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Supplemental TABLE 1. Baseline Characteristics According to GALECTIN-3 by Quartiles 
 Q1, N=74 Q2, N=73 Q3, N=74 Q4, N=73 P for trend  
Age, years  68 ± 10 73 ± 8 72 ± 9 72 ± 9 0.020 
Women (%) 36     (48.6%) 39     (53.4%) 41     (55.4%) 49     (67.1%) 0.027 
NYHA Class I 1      (1.4%) 1      (1.4%) 0      (0.0%) 0      (0.0%)  0.12 
NYHA Class II 61     (82.4%) 58     (79.5%) 60     (81.1%) 54     (74.0%)   
NYHA Class III 12     (16.2%) 14     (19.2%) 14     (18.9%) 19     (26.0%)   
Previous admission for heart failure 24     (32.4%) 32     (43.8%) 26     (35.1%) 40     (54.8%) 0.023 
History of atrial fibrillation 31     (41.9%) 29     (39.7%) 29     (39.2%) 33     (45.2%) 0.72 
Atrial fibrillation at screening ECG 20     (27.0%) 20     (27.4%) 20     (27.0%) 23     (31.5%) 0.58 
History of hypertension 66     (89.2%) 72     (98.6%) 66     (89.2%) 72     (98.6%) 0.13 
History of diabetes 25     (33.8%) 24     (32.9%) 29     (39.2%) 33     (45.2%) 0.11 
History of myocardial infarction 14     (18.9%) 17     (23.3%) 19     (25.7%) 9      (12.3%) 0.41 
NT-proBNP (pg/mL), median [Q1, Q3] 693.0 [368.0, 1377.0] 867.0 [499.0, 1341.0] 909.5 [512.0, 1269.5] 962.0 [628.0, 1960.5] 0.014 
Heart rate (bpm) 67.15 ± 11.76 68.03 ± 11.66 69.77 ± 12.18 72.26 ± 15.71 0.012 
Body mass index (kg/m2) 29.90 ± 5.60 29.60 ± 5.22 30.47 ± 5.87 30.00 ± 6.38 0.70 
Systolic BP (mmHg) 134.65 ± 15.06 136.29 ± 14.17 136.10 ± 13.11 133.87 ± 13.66 0.73 
Diastolic BP (mmHg) 79.31 ± 8.65 77.73 ± 9.79 77.88 ± 7.61 74.95 ± 10.93 0.008 
eGFR (mL/min per 1.73 m²) 76.18 ± 20.31 68.40 ± 15.46 65.10 ± 17.35 51.13 ± 19.61 <0.001 
ACE inhibitors or ARBs 67     (90.5%) 68     (93.2%) 73     (98.6%) 67     (91.8%) 0.47 
Beta blockers 58     (78.4%) 61     (83.6%) 59     (79.7%) 53     (72.6%) 0.33 
Aldosterone antagonists 9      (12.2%) 16     (21.9%) 19     (25.7%) 18     (24.7%) 0.05  
E' (cm/s) 7.77 ± 2.92 7.02 ± 2.48 7.43 ± 3.05 7.64 ± 2.46 0.57 
E/E' 11.41 ± 4.55 13.40 ± 6.89 12.74 ± 6.42 12.70 ± 5.69 0.17 
LA volume index (mL/m²) 35.46 ± 12.54 35.90 ± 14.93 37.08 ± 15.57 34.50 ± 11.35 0.84 
LV end diastolic volume (mL) 118.37 ± 29.41 115.44 ± 33.84 107.42 ± 26.09 107.70 ± 23.68 0.11 
LV ejection fraction (%) 56.65 ± 7.00 57.89 ± 9.71 59.62 ± 7.16 58.81 ± 6.77 0.06 
LV mass index (g/m²) 73.23 ± 17.35 81.46 ± 25.00 77.92 ± 21.16 77.39 ± 20.80 0.29 
Relative wall thickness 0.35 ± 0.05 0.37 ± 0.07 0.37 ± 0.08 0.38 ± 0.08 0.004 
Tricuspid regurgitant velocity (m/s) 2.43 ± 0.33 2.50 ± 0.36 2.60 ± 0.32 2.47 ± 0.49 0.31 
LA strain (%) 22.10 ± 9.31 19.84 ± 7.15 22.34 ± 8.68 19.83 ± 6.24 0.40 
LV global longitudinal strain (%) -14.57 ± 3.52 -14.56 ± 3.20 -15.16 ± 3.48 -14.20 ± 3.09 0.79  
3 3/30/16 
 
 
 
Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
4 3/30/16 
 
 
 
Supplemental TABLE 2. Baseline Characteristics According to MMP-2 Quartiles 
 Q1  N=62 Q2 N=62 Q3 N=62 Q4 N=61 P for trend  
Age, years  68 ± 10 72 ± 9 73 ± 8 73 ± 8 0.003 
Women (%) 36     (58.1%) 32     (51.6%) 38     (61.3%) 34     (55.7%) 0.92 
NYHA Class I 0      (0.0%) 1      (1.6%) 1      (1.6%) 0      (0.0%)  0.30 
NYHA Class II 53     (85.5%) 51     (82.3%) 46     (74.2%) 49     (80.3%)   
NYHA Class III 9      (14.5%) 10     (16.1%) 15     (24.2%) 12     (19.7%)   
Previous admission for heart failure 26     (41.9%) 20     (32.3%) 24     (38.7%) 26     (42.6%) 0.76 
History of atrial fibrillation 22     (35.5%) 30     (48.4%) 29     (46.8%) 27     (44.3%) 0.38 
Atrial fibrillation at screening ECG 14     (22.6%) 22     (35.5%) 16     (25.8%) 21     (34.4%) 0.32 
History of hypertension 58     (93.5%) 58     (93.5%) 57     (91.9%) 57     (93.4%) 0.89 
History of diabetes 19     (30.6%) 21     (33.9%) 22     (35.5%) 27     (44.3%) 0.12 
History of myocardial infarction 17     (27.4%) 16     (25.8%) 10     (16.1%) 9      (14.8%) 0.04 
NT-proBNP (pg/mL), median [Q1, Q3] 573.0 [346.5, 1022.5] 766.5 [387.0, 1273.0] 973.5 [645.0, 1590.0] 1154.0 [744.0,1853.0] <0.001 
Heart rate (bpm) 69.87 ± 12.70 67.59 ± 11.40 68.53 ± 15.40 68.02 ± 11.90 0.53 
Body mass index (kg/m2) 30.34 ± 5.61 30.19 ± 5.24 31.17 ± 6.15 30.11 ± 5.50 0.92 
Systolic BP (mmHg) 135.13 ± 14.22 136.55 ± 14.61 133.15 ± 12.00 137.16 ± 15.22 0.74 
Diastolic BP (mmHg) 80.27 ± 9.17 78.62 ± 10.01 76.57 ± 8.45 74.00 ± 10.05 <0.001 
eGFR (mL/min per 1.73 m²) 71.82 ± 21.46 66.18 ± 17.27 65.97 ± 22.51 59.52 ± 16.78 0.001 
ACE inhibitors or ARBs 60     (96.8%) 56     (90.3%) 57     (91.9%) 57     (93.4%) 0.56 
Beta blockers 47     (75.8%) 50     (80.6%) 50     (80.6%) 54     (88.5%) 0.09 
Aldosterone antagonists 14     (22.6%) 11     (17.7%) 16     (25.8%) 13     (21.3%) 0.86  
E' (cm/s) 6.85 ± 2.74 7.44 ± 2.91 6.92 ± 2.59 8.45 ± 2.80 0.17 
E/E' 11.44 ± 5.18 11.72 ± 5.38 14.86 ± 6.77 12.79 ± 6.35 0.013 
LA volume index (mL/m²) 33.13 ± 13.09 35.78 ± 13.58 37.12 ± 14.13 38.03 ± 13.32 0.042 
LV end diastolic volume (mL) 114.89 ± 31.94 115.91 ± 26.66 106.07 ± 24.37 114.51 ± 31.76 0.31 
LV ejection fraction (%) 57.47 ± 8.54 57.86 ± 8.95 59.19 ± 7.48 59.87 ± 6.08 0.028 
LV mass index (g/m²) 75.58 ± 20.12 78.31 ± 21.32 75.04 ± 20.53 79.58 ± 21.49 0.98 
Relative wall thickness 0.37 ± 0.06 0.37 ± 0.07 0.37 ± 0.05 0.38 ± 0.09 0.48 
Tricuspid regurgitant velocity (m/s) 2.41 ± 0.29 2.35 ± 0.15 2.58 ± 0.45 2.64 ± 0.45 0.004 
LA strain (%) 22.57 ± 7.70 21.24 ± 8.72 20.72 ± 6.92 20.55 ± 8.61 0.22 
LV global longitudinal strain (%) -15.25 ± 3.85 -15.03 ± 2.97 -14.42 ± 3.18 -15.18 ± 3.09 0.68  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 3. Baseline Characteristics According to PIIINP Quartiles 
 Q1 N=45 Q2 N=44 Q3 N=44 Q4 N=45 P for trend  
Age, years  70 ± 10 70 ± 11 72 ± 8 73 ± 9 0.06 
Women (%) 22     (48.9%) 25     (56.8%) 25     (55.6%) 27     (61.4%) 0.28 
NYHA Class I 0      (0.0%) 0      (0.0%) 1      (2.2%) 1      (2.3%)  0.88 
NYHA Class II 37     (82.2%) 34     (77.3%) 36     (80.0%) 34     (77.3%)  
NYHA Class III 8      (17.8%) 10     (22.7%) 8      (17.8%) 9      (20.5%)  
Previous admission for heart failure 18     (40.0%) 14     (31.8%) 20     (44.4%) 9      (20.5%) 0.15 
History of atrial fibrillation 20     (44.4%) 19     (43.2%) 23     (51.1%) 20     (45.5%) 0.74 
Atrial fibrillation at screening ECG 15     (33.3%) 13     (29.5%) 17     (37.8%) 12     (27.3%) 0.76 
History of hypertension 44     (97.8%) 40     (90.9%) 40     (88.9%) 43     (97.7%) 0.88 
History of diabetes 23     (51.1%) 10     (22.7%) 14     (31.1%) 14     (31.8%) 0.12 
History of myocardial infarction 15     (33.3%) 13     (29.5%) 7      (15.6%) 8      (18.2%) 0.142 
NT-proBNP (pg/mL), median [Q1, Q3] 511.0 [369.0, 1018.0] 796.0 [517.0, 1267.0] 1107.0 [572.0,1800.0] 967.0 [625.0, 1507.0] 0.001 
Heart rate (bpm) 67.73 ± 12.54 65.09 ± 9.77 68.11 ± 11.91 73.36 ± 15.13 0.020 
Body mass index (kg/m2) 30.40 ± 4.38 30.32 ± 5.18 29.90 ± 5.84 31.79 ± 6.67 0.32 
Systolic BP (mmHg) 135.47 ± 12.81 133.42 ± 13.05 137.43 ± 13.96 133.87 ± 11.51 0.93 
Diastolic BP (mmHg) 79.79 ± 8.76 77.58 ± 9.56 78.32 ± 10.12 76.88 ± 9.76 0.21 
eGFR (mL/min per 1.73 m²) 72.20 ± 18.41 70.14 ± 20.06 65.82 ± 18.07 63.79 ± 17.54 0.019 
ACE inhibitors or ARBs 40     (88.9%) 43     (97.7%) 43     (95.6%) 41     (93.2%) 0.50 
Beta blockers 37     (82.2%) 34     (77.3%) 40     (88.9%) 35     (79.5%) 0.89 
Aldosterone antagonists 9      (20.0%) 11     (25.0%) 12     (26.7%) 6      (13.6%) 0.54  
E' (cm/s) 7.33 ± 2.70 7.58 ± 2.73 7.57 ± 2.98 8.19 ± 2.90 0.30 
E/E' 11.74 ± 5.66 13.39 ± 7.19 13.06 ± 5.72 11.03 ± 4.85 0.56 
LA volume index (mL/m²) 32.74 ± 12.62 38.87 ± 13.36 37.76 ± 13.05 33.83 ± 16.06 0.83 
LV end diastolic volume (mL) 122.27 ± 31.17 108.15 ± 27.74 116.64 ± 31.47 108.56 ± 22.50 0.16 
LV ejection fraction (%) 57.16 ± 8.41 57.87 ± 6.81 58.82 ± 9.70 60.45 ± 7.71 0.033 
LV mass index (g/m²) 74.45 ± 23.32 75.40 ± 17.25 73.08 ± 20.08 75.05 ± 20.04 0.96 
Relative wall thickness 0.35 ± 0.08 0.35 ± 0.06 0.37 ± 0.06 0.37 ± 0.06 0.17 
Tricuspid regurgitant velocity (m/s) 2.42 ± 0.35 2.53 ± 0.36 2.51 ± 0.36 2.52 ± 0.30 0.68 
LA strain (%) 22.78 ± 7.44 18.80 ± 7.71 21.96 ± 8.89 23.31 ± 8.26 0.52 
LV global longitudinal strain (%) -15.39 ± 3.17 -14.67 ± 2.96 -15.22 ± 3.22 -15.55 ± 2.77 0.72  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 4. Baseline Characteristics According to sST-2 Quartiles 
 Q1 N=74 Q2 N=74 Q3 N=74 Q4 N=74 P for trend  
Age, years  69 ± 10 70 ± 10 71 ± 8 74 ± 8 0.004 
Women (%) 47     (63.5%) 45     (60.8%) 38     (51.4%) 36     (48.6%) 0.036 
NYHA Class I 0      (0.0%) 1      (1.4%) 1      (1.4%) 0      (0.0%)  0.043 
NYHA Class II 66     (89.2%) 55     (74.3%) 59     (79.7%) 54     (73.0%)  
NYHA Class III 8      (10.8%) 18     (24.3%) 14     (18.9%) 20     (27.0%)  
Previous admission for heart failure 28     (37.8%) 29     (39.2%) 33     (44.6%) 34     (45.9%) 0.25 
History of atrial fibrillation 17     (23.0%) 32     (43.2%) 33     (44.6%) 39     (52.7%) <0.001 
Atrial fibrillation at screening ECG 7      (9.5%) 20     (27.0%) 22     (29.7%) 33     (44.6%) <0.001 
History of hypertension 66     (89.2%) 72     (97.3%) 73     (98.6%) 67     (90.5%) 0.66 
History of diabetes 26     (35.1%) 21     (28.4%) 34     (45.9%) 32     (43.2%) 0.10 
History of myocardial infarction 20     (27.0%) 14     (18.9%) 13     (17.6%) 14     (18.9%) 0.22 
NT-proBNP (pg/mL), median [Q1, Q3] 773.5 [355.0, 1247.5] 715.5 [393.0, 1341.0] 957.0 [601.0, 1322.0] 1014.0 [603.0,1800.0] 0.002 
Heart rate (bpm) 69.23 ± 13.28 67.59 ± 10.67 70.18 ± 14.45 70.01 ± 13.46 0.47 
Body mass index (kg/m2) 28.57 ± 5.26 30.52 ± 6.23 30.61 ± 5.38 30.24 ± 6.09 0.09 
Systolic BP (mmHg) 134.34 ± 13.40 137.82 ± 13.19 134.34 ± 13.62 134.84 ± 15.93 0.79 
Diastolic BP (mmHg) 77.78 ± 7.73 80.02 ± 10.24 77.79 ± 8.03 73.79 ± 10.60 0.004 
eGFR (mL/min per 1.73 m²) 69.12 ± 21.46 68.47 ± 19.88 62.32 ± 20.74 61.19 ± 18.14 0.005 
ACE inhibitors or ARBs 72     (97.3%) 69     (93.2%) 67     (90.5%) 68     (91.9%) 0.15 
Beta blockers 55     (74.3%) 58     (78.4%) 61     (82.4%) 59     (79.7%) 0.34 
Aldosterone antagonists 9      (12.2%) 13     (17.6%) 22     (29.7%) 18     (24.3%) 0.021  
E' (cm/s) 7.10 ± 2.69 7.43 ± 2.77 7.72 ± 2.60 7.54 ± 2.99 0.30 
E/E' 10.98 ± 3.87 12.57 ± 6.00 13.29 ± 6.85 13.70 ± 6.63 0.06 
LA volume index (mL/m²) 31.67 ± 11.70 35.10 ± 12.93 36.40 ± 13.94 39.83 ± 14.90 <0.001 
LV end diastolic volume (mL) 114.79 ± 29.12 106.59 ± 22.81 111.27 ± 29.73 120.46 ± 33.43 0.35 
LV ejection fraction (%) 57.88 ± 9.10 58.83 ± 7.20 58.46 ± 7.25 57.33 ± 7.59 0.71 
LV mass index (g/m²) 76.34 ± 18.92 77.54 ± 21.03 79.36 ± 25.66 77.16 ± 18.49 0.76 
Relative wall thickness 0.37 ± 0.07 0.36 ± 0.06 0.37 ± 0.08 0.37 ± 0.06 0.61 
Tricuspid regurgitant velocity (m/s) 2.38 ± 0.29 2.54 ± 0.31 2.52 ± 0.40 2.58 ± 0.44 0.42 
LA strain (%) 23.94 ± 8.92 20.15 ± 7.80 21.04 ± 7.53 19.78 ± 7.46 0.025 
LV global longitudinal strain (%) -14.56 ± 3.61 -14.19 ± 3.02 -15.06 ± 3.51 -14.85 ± 3.21 0.39  
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Abbreviations: 
sST-2 = soluble form of ST2(an Interleukin-1 receptor family member), ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, 
eGFR = estimated glomerular filtration rate, NYHA = New York Heart Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = 
blood pressure, continuous data are presented as mean ± standard deviation, categorical data are presented as frequency and % of total. E = early 
diastolic filling velocity, E’ = early diastolic myocardial velocity, LA = left atrium, LV = left ventricular 
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